CLINICAL TRIALS PROFILE FOR CRIZOTINIB
✉ Email this page to a colleague
All Clinical Trials for crizotinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00828919 ↗ | Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials | Active, not recruiting | Pfizer | N/A | 2003-03-07 | To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial |
| NCT00939770 ↗ | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2009-09-21 | This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13) |
| NCT00939770 ↗ | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | Pfizer | Phase 1/Phase 2 | 2009-09-21 | This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13) |
| NCT00939770 ↗ | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | Children's Oncology Group | Phase 1/Phase 2 | 2009-09-21 | This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13) |
| NCT01082380 ↗ | Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers | Completed | Pfizer | Phase 1 | 2010-03-01 | The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans. |
| NCT01121588 ↗ | An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) | Active, not recruiting | Pfizer | Phase 1 | 2011-03-22 | This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for crizotinib
Condition Name
Clinical Trial Locations for crizotinib
Trials by Country
Clinical Trial Progress for crizotinib
Clinical Trial Phase
Clinical Trial Sponsors for crizotinib
Sponsor Name
